Treatment Resistant Depression Market Report and Forecast 2024-2032

Treatment Resistant Depression Market Report and Forecast 2024-2032


Treatment Resistant Depression Market Report and Forecast 2024-2032

Treatment Resistant Depression Market Outlook

The treatment resistant depression market size was valued at USD 2.8 billion in 2023, driven growing emphasis on personalized or precision medicine across the major markets. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032, with the values likely to rise to USD 4.9 billion by 2032.

Treatment Resistant Depression: Introduction

Treatment-resistant depression (TRD) refers to major depressive disorder (MDD) that does not respond adequately to at least two different antidepressant treatments given at adequate doses and durations. TRD poses significant challenges in mental health care, leading to prolonged suffering and increased risk of suicide. Management strategies may include medication adjustments, adding adjunctive therapies, psychotherapy, and considering alternative treatments like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or ketamine infusions to alleviate symptoms and improve quality of life.

Key Trends in the Treatment Resistant Depression Market

There is a growing trend towards personalized or precision medicine in treating TRD, involving genetic testing and biomarker analysis to tailor treatment strategies to individual patient profiles. This approach aims to improve treatment efficacy and reduce trial-and-error prescribing.

Neuromodulation techniques such as Transcranial Magnetic Stimulation (TMS) and Electroconvulsive Therapy (ECT) are gaining traction as effective treatments for TRD. The development and approval of newer neuromodulation technologies, including Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS), reflect this trend.

The market is seeing an influx of novel pharmacotherapies targeting mechanisms of action different from traditional antidepressants. Drugs like esketamine, approved for TRD, represent this shift towards innovative treatment modalities offering rapid relief of symptoms.

Digital health technologies, including telepsychiatry, mobile apps for mental health management, and wearable devices for monitoring physiological markers, are becoming integral to managing TRD. These technologies support remote monitoring, patient engagement, and personalized care plans.

There is a notable shift towards comprehensive, multidisciplinary care models that address the multifaceted nature of TRD. These models incorporate pharmacological treatments, psychotherapy, lifestyle modifications, and social support to address the broad spectrum of needs among individuals with TRD.

Collaborative research efforts and partnerships between academic institutions, pharmaceutical companies, and mental health organizations are vital in advancing the understanding and treatment of TRD. These collaborations are crucial for driving innovation in therapeutic approaches and developing new treatment paradigms.

Treatment Resistant Depression Market Segmentation

Market Breakup by Drug Class
  • Selective Serotonin Reuptake Inhibitors (SSRIS)
  • Monoamine Oxidase Inhibitors
  • Tricyclic Antidepressant
  • Psychedelics
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Treatment Resistant Depression Market Overview

In North America, the market for treatment-resistant depression (TRD) is advanced, with a strong emphasis on developing and adopting innovative therapies. There's a significant focus on personalized medicine approaches, including genetic testing to tailor antidepressant treatments. The region has seen the approval and increased use of novel treatment options such as ketamine and esketamine nasal spray, alongside non-pharmacological interventions like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). Awareness and acceptance of mental health issues are high, driving demand for effective TRD treatments.

Europe's TRD market is characterized by comprehensive healthcare systems that support access to a wide range of treatments, including pharmacological interventions, psychotherapy, and novel therapies. The region shows a strong commitment to mental health research, with ongoing trials exploring new treatment modalities. Regulatory bodies in Europe have been proactive in evaluating and approving new therapies, with a growing interest in digital health solutions and interventions to support individuals with TRD.

In Japan, the market for TRD treatment reflects the country's high standard of healthcare and openness to innovative treatment techniques. Japan has a keen interest in integrating technology into healthcare, leading to the exploration of digital therapeutics and mobile applications for managing depression. The adoption of new pharmacological treatments is carefully regulated, with a growing interest in evidence-based alternative treatments. Public and private sector collaboration is evident in efforts to address the stigma associated with mental health and improve access to care for individuals with TRD.

Treatment Resistant Depression Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Pfizer Inc
  • Mylan N.V.
  • Hikma Pharmaceuticals plc
  • AbbVie Inc.
  • Melinta Therapeutics, Inc
  • Bristol Myers Squibb Company
  • GSK Plc.
  • Bayer AG
  • Perrigo Company plc
  • Johnson & Johnson Services, Inc
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Teva Pharmaceutical Industries Ltd
  • Endo Pharmaceuticals plc
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Treatment Resistant Depression Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Treatment Resistant Depression Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.1 Germany Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.2 France Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.3 Italy Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.4 Spain Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.4 Japan Treatment Resistant Depression Epidemiology Forecast (2017-2032)
6 Treatment Resistant Depression Market Overview – 7MM
6.1 Treatment Resistant Depression Market Historical Value (2017-2023)
6.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
7 Treatment Resistant Depression Market Landscape – 7MM
7.1 Treatment Resistant Depression: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Treatment Resistant Depression Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
8 Treatment Resistant Depression Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Treatment Resistant Depression Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Treatment Resistant Depression Market Segmentation – 7MM
11.1 Treatment Resistant Depression Market by Drug Class
11.1.1 Market Overview
11.1.2 Selective Serotonin Reuptake Inhibitors (SSRIS)
11.1.3 Monoamine Oxidase Inhibitors
11.1.4 Tricyclic Antidepressant
11.1.5 Psychedelics
11.1.6 Others
11.2 Treatment Resistant Depression Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Others
11.3 Treatment Resistant Depression Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Specialty Clinics
11.3.4 Others
11.4 Treatment Resistant Depression Market by Distribution Channel
11.4.1 Hospital Pharmacy
11.4.2 Retail Pharmacy
11.4.3 Online Pharmacy
11.5 Treatment Resistant Depression Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Treatment Resistant Depression Market
12.1 Treatment Resistant Depression Market Historical Value (2017-2023)
12.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
12.3 Treatment Resistant Depression Market by Drug Class
12.4 Treatment Resistant Depression Market by Route of Administration
13 EU-4 and United Kingdom Treatment Resistant Depression Market
13.1 Treatment Resistant Depression Market Historical Value (2017-2023)
13.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
13.3 Germany Treatment Resistant Depression Market Overview
13.3.1 Treatment Resistant Depression Market by Drug Class
13.3.2 Treatment Resistant Depression Market by Route of Administration
13.4 France Treatment Resistant Depression Market Overview
13.4.1 Treatment Resistant Depression Market by Drug Class
13.4.2 Treatment Resistant Depression Market by Route of Administration
13.5 Italy Treatment Resistant Depression Market Overview
13.5.1 Treatment Resistant Depression Market by Drug Class
13.5.2 Treatment Resistant Depression Market by Route of Administration
13.6 Spain Treatment Resistant Depression Market Overview
13.6.1 Treatment Resistant Depression Market by Drug Class
13.6.2 Treatment Resistant Depression Market by Route of Administration
13.7 United Kingdom Treatment Resistant Depression Market Overview
13.7.1 Treatment Resistant Depression Market by Drug Class
13.7.2 Treatment Resistant Depression Market by Route of Administration
14 Japan Treatment Resistant Depression Market
14.1 Treatment Resistant Depression Market Historical Value (2017-2023)
14.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
14.3 Treatment Resistant Depression Market by Drug Class
14.4 Treatment Resistant Depression Market by Route of Administration
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mylan N.V.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Hikma Pharmaceuticals plc
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Melinta Therapeutics, Inc
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bristol Myers Squibb Company
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 GSK Plc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Perrigo Company plc
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Johnson & Johnson Services, Inc
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amneal Pharmaceuticals LLC. (U.S.)
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Teva Pharmaceutical Industries Ltd
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Endo Pharmaceuticals plc
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Currax Pharmaceuticals LLC
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Eli Lilly and Company
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Treatment Resistant Depression Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings